Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Life Sciences Industry Analysis

UpdatedApr 15, 2026
DataAggregated Company Financials
Companies7
  • 7D7.4%
  • 3M-3.1%
  • 1Y2.4%
  • YTD3.1%

In the last week, the Life Sciences industry is up 7.4%, with Lonza Group up 5.2%. The industry has been flat over the past 12 months despite the gain this week. As for the next few years, earnings are expected to grow by 19% per annum.

Industry Valuation and Performance

Has the Swiss Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 15 Apr 2026CHF 50.3bCHF 10.1bCHF 1.1b37.4x44x5x
Fri, 13 Mar 2026CHF 45.6bCHF 10.1bCHF 1.3b29x35.3x4.5x
Sun, 08 Feb 2026CHF 49.5bCHF 10.1bCHF 1.3b32.4x38.8x4.9x
Tue, 06 Jan 2026CHF 49.1bCHF 10.6bCHF 1.1b29.7x44.6x4.6x
Thu, 04 Dec 2025CHF 49.9bCHF 10.6bCHF 1.1b28.9x45.4x4.7x
Sat, 01 Nov 2025CHF 50.7bCHF 10.6bCHF 1.1b31x46.1x4.8x
Mon, 29 Sep 2025CHF 48.4bCHF 10.6bCHF 1.1b30.8x44x4.5x
Wed, 27 Aug 2025CHF 54.2bCHF 10.6bCHF 1.1b35.4x49.1x5.1x
Fri, 25 Jul 2025CHF 54.6bCHF 10.6bCHF 1.1b37.2x48x5.1x
Sun, 22 Jun 2025CHF 52.5bCHF 10.1bCHF 1.0b33.3x50.6x5.2x
Tue, 20 May 2025CHF 53.3bCHF 10.1bCHF 1.0b32.8x51.3x5.3x
Thu, 17 Apr 2025CHF 49.6bCHF 10.1bCHF 1.0b28.5x48.3x4.9x
Sat, 15 Mar 2025CHF 52.1bCHF 10.1bCHF 1.0b33.2x51.6x5.2x
Mon, 10 Feb 2025CHF 57.7bCHF 10.1bCHF 1.0b35.9x57.3x5.7x
Wed, 08 Jan 2025CHF 54.4bCHF 10.2bCHF 943.4m36.4x57.7x5.3x
Fri, 06 Dec 2024CHF 52.4bCHF 10.2bCHF 943.7m39.4x55.5x5.1x
Sun, 03 Nov 2024CHF 55.6bCHF 10.2bCHF 943.3m42.2x58.9x5.4x
Tue, 01 Oct 2024CHF 55.4bCHF 10.2bCHF 943.3m42.4x58.7x5.4x
Thu, 29 Aug 2024CHF 57.7bCHF 10.2bCHF 937.1m45x61.5x5.6x
Sat, 27 Jul 2024CHF 59.4bCHF 10.3bCHF 1.0b45.3x59.1x5.8x
Mon, 24 Jun 2024CHF 51.3bCHF 10.3bCHF 1.0b44.2x51.1x5x
Wed, 22 May 2024CHF 54.5bCHF 10.3bCHF 1.0b44.7x54.4x5.3x
Fri, 19 Apr 2024CHF 53.5bCHF 10.3bCHF 1.0b43x53.3x5.2x
Sun, 17 Mar 2024CHF 52.8bCHF 10.2bCHF 1.0b44.7x52.6x5.2x
Tue, 13 Feb 2024CHF 48.5bCHF 10.2bCHF 1.0b43.3x47.6x4.8x
Thu, 11 Jan 2024CHF 42.0bCHF 9.8bCHF 1.5b31.5x28.1x4.3x
Sat, 09 Dec 2023CHF 39.3bCHF 9.8bCHF 1.5b29.9x26.3x4x
Mon, 06 Nov 2023CHF 38.8bCHF 9.8bCHF 1.5b27.3x26x4x
Wed, 04 Oct 2023CHF 46.0bCHF 9.8bCHF 1.5b31.7x30.8x4.7x
Fri, 01 Sep 2023CHF 53.3bCHF 9.8bCHF 1.5b36.8x35.7x5.5x
Sun, 30 Jul 2023CHF 53.8bCHF 9.8bCHF 1.5b36.8x34.8x5.5x
Tue, 27 Jun 2023CHF 54.0bCHF 9.7bCHF 1.6b33.8x33.1x5.6x
Thu, 25 May 2023CHF 59.5bCHF 9.7bCHF 1.6b38.1x36.4x6.1x
Sat, 22 Apr 2023CHF 60.7bCHF 9.7bCHF 1.7b42.8x36.4x6.3x
Price to Earnings Ratio

36.4x


Total Market Cap: CHF 60.7bTotal Earnings: CHF 1.7bTotal Revenue: CHF 9.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Life Sciences Industry Price to Earnings3Y Average 46x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swiss Life Sciences industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 46.0x.
  • The industry is trading close to its 3-year average PS ratio of 5.1x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have declined 12% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market4.04%
Healthcare2.62%
Life Sciences7.43%
Clinical Research and Equipment7.43%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LONN Lonza GroupCHF 533.805.0%
+CHF 1.8b		-1.4%PE41x
BANB Bachem HoldingCHF 73.0014.2%
+CHF 678.2m		52.5%PE36.8x
SFZN Siegfried HoldingCHF 83.508.9%
+CHF 297.9m		-5.8%PE21.7x
PPGN PolyPeptide GroupCHF 37.2524.6%
+CHF 242.6m		139.1%PS3.4x
SKAN SKAN GroupCHF 47.6512.2%
+CHF 116.9m		-23.5%PE65.8x

Latest News

LONN
CHF 533.80
Lonza Group
7D
5.0%
1Y
-1.4%
SKAN
CHF 47.65
SKAN Group
7D
12.2%
1Y
-23.5%
BANB
CHF 73.00
Bachem Holding
7D
14.2%
1Y
52.5%
TECN
CHF 141.40
Tecan Group
7D
4.4%
1Y
-1.7%
SFZN
CHF 83.50
Siegfried Holding
7D
8.9%
1Y
-5.8%

SFZN: Lower Street Expectations Will Support Future Upside Potential

Analysts now see Siegfried's fair value aligning with a lower Street view, with a key price target reset to CHF 96 from CHF 108 as they highlight more balanced expectations following the recent downgrade. Analyst Commentary Recent Street commentary around Siegfried reflects a more cautious stance, with price targets reset and ratings adjusted to align expectations more closely with current execution and valuation risks.
PPGN
CHF 37.25
PolyPeptide Group
7D
24.6%
1Y
139.1%